CEACAM5 and rectal cancer: Patients with rectal cancer (5-year OS: 96.6% vs. 94.0%; p = 0.013) (Figure 1A), elevated CEA levels (5-year OS: 96.7% vs. 92.1%, p < 0.001), or recurrence (5-year OS: 97.1% vs. 67.6%, p < 0.001) (Figure 1B) had a decreased OS rate.